Let's look beyond this piece of bad news from regulators.Vaccine maker Novavax (NVAX -1.64%) has had a rollercoaster of a year. In May, the company's shares soared after it announced a lucrative agreement with biotech giant Sanofi. It's been mostly downhill for Novavax since then, though that's likely due to some profit taking by investors.However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock price is still up by more than 100% for the ...